The Full Federal Court has held that the (+) enantiomer of citalopram is itself a pharmaceutical substance per se and so eligible for term extension
The High Court has dismissed Astrazeneca’s appeal against the finding that its rosuvastatin patent was obvious.
Nicholas J stays dissolution of interlocutory injunction pending Otsuka’s appeal from invalidity of aripiprazole patent judgment. Commonwealth gets security for undertaking as to damages.
Minister announce Productivity Commission to review Australia’s IP laws
IP Australia issues consultation paper on ACIP’s report into the innovation patent system
WIPO has published 2 studies on inventive step and sufficiency of disclosure in patent laws.
ACIP now recommends abolition of the innovation patent system
Having had the interlocutory injunction he granted overturned on appeal, Rares J has now determined at the substantive trial that both of Glaxo’s syringe variants infringed Reckitt Benkiser’s “flat-nosed syringe” patent.
Sanofi sued Apotex (then known as GenRx) for infringement of its “clopidogrel patent”. It obtained interlocutory injunctions against Apotex against the sale of Apotex’ product and preventing Apotex from applying to list its product under the Pharmaceutical Benefits scheme (PBS). As a condition of the grant of those interlocutory injunctions, Sanofi gave the “usual undertaking as to damages”: “(a) submit to such order (if any) as the Court may consider to.. Read More
IP Australia has released the Australian Intellectual Property Report 2015, with statistics on IP filings and grants and trends.